• Something wrong with this record ?

Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells

E. Cadoni, P. Vanhara, E. Valletta, E. Pinna, S. Vascellari, G. Caddeo, F. Isaia, A. Pani, J. Havel, T. Pivetta,

. 2019 ; 33 (1) : 97-106.

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19012205

RATIONALE: Development of therapy-resistant cancer is a major problem in clinical oncology, and there is an urgent need for novel markers identifying development of the resistant phenotype. Lipidomics represents a promising approach to discriminate lipid profiles of malignant phenotype cells. Alterations in phospholipid distribution or chemical composition have been reported in various pathologies including cancer. Here we were curious whether quantitative differences in phospholipid composition between cisplatin-resistant and -sensitive model cancer cell lines could be revealed by mass spectrometric means. METHODS: The phospholipid contents of cell membranes of the cancer cell lines CCRF-CEM and A2780, both responsive and resistant to cisplatin, were analyzed by solid-phase extraction (SPE) and electrospray ionization mass spectrometry (ESI-MS and tandem mass spectrometry (MS/MS)). Extracts were obtained by disruption of cells with a dounce tissue grinder set followed by centrifugation. To minimize the enzymatic activity, phospholipids were extracted from cell extracts by SPE immediately after the cell lysis and analyzed by MS. Both supernatant and pellet fractions of cell extracts were analyzed. RESULTS: A phospholipid profile specific for cell lines and their phenotypes was revealed. We have documented by quantitative analysis that phosphocholines PC P-34:0, PC 34:1, PC 20:2_16:0, LPC 18:1 and LPC 16:0 PLs were present in the 200-400 μM concentration range in CCRF-CEM cisplatin-responsive cells, but absent in their cisplatin-resistant cells. Similarly, PC 34:1, LPC 18:1 and LPC 16:0 were increased in cisplatin-responsive A2780 cells, and PC 20:2_16:0 was downregulated in cisplatin-resistant A2780 cells. CONCLUSIONS: In this work we showed that the ESI-MS analysis of the lipid content of the therapy-resistant and -sensitive cells can clearly distinguish the phenotypic pattern and determine the potential tumor response to cytotoxic therapy. Lipid entities revealed by mass spectrometry and associated with development of therapy resistance can thus support molecular diagnosis and provide a potential complementary cancer biomarker.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012205
003      
CZ-PrNML
005      
20190416084246.0
007      
ta
008      
190405s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/rcm.8320 $2 doi
035    __
$a (PubMed)30376198
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Cadoni, Enzo $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
245    10
$a Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells / $c E. Cadoni, P. Vanhara, E. Valletta, E. Pinna, S. Vascellari, G. Caddeo, F. Isaia, A. Pani, J. Havel, T. Pivetta,
520    9_
$a RATIONALE: Development of therapy-resistant cancer is a major problem in clinical oncology, and there is an urgent need for novel markers identifying development of the resistant phenotype. Lipidomics represents a promising approach to discriminate lipid profiles of malignant phenotype cells. Alterations in phospholipid distribution or chemical composition have been reported in various pathologies including cancer. Here we were curious whether quantitative differences in phospholipid composition between cisplatin-resistant and -sensitive model cancer cell lines could be revealed by mass spectrometric means. METHODS: The phospholipid contents of cell membranes of the cancer cell lines CCRF-CEM and A2780, both responsive and resistant to cisplatin, were analyzed by solid-phase extraction (SPE) and electrospray ionization mass spectrometry (ESI-MS and tandem mass spectrometry (MS/MS)). Extracts were obtained by disruption of cells with a dounce tissue grinder set followed by centrifugation. To minimize the enzymatic activity, phospholipids were extracted from cell extracts by SPE immediately after the cell lysis and analyzed by MS. Both supernatant and pellet fractions of cell extracts were analyzed. RESULTS: A phospholipid profile specific for cell lines and their phenotypes was revealed. We have documented by quantitative analysis that phosphocholines PC P-34:0, PC 34:1, PC 20:2_16:0, LPC 18:1 and LPC 16:0 PLs were present in the 200-400 μM concentration range in CCRF-CEM cisplatin-responsive cells, but absent in their cisplatin-resistant cells. Similarly, PC 34:1, LPC 18:1 and LPC 16:0 were increased in cisplatin-responsive A2780 cells, and PC 20:2_16:0 was downregulated in cisplatin-resistant A2780 cells. CONCLUSIONS: In this work we showed that the ESI-MS analysis of the lipid content of the therapy-resistant and -sensitive cells can clearly distinguish the phenotypic pattern and determine the potential tumor response to cytotoxic therapy. Lipid entities revealed by mass spectrometry and associated with development of therapy resistance can thus support molecular diagnosis and provide a potential complementary cancer biomarker.
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cisplatina $x farmakologie $7 D002945
650    12
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory vaječníků $x chemie $x farmakoterapie $x patologie $7 D010051
650    _2
$a fosfolipidy $x analýza $x chemie $7 D010743
650    _2
$a lymfoblastická leukemie-lymfom z prekurzorových T-buněk $x farmakoterapie $x patologie $7 D054218
650    _2
$a extrakce na pevné fázi $7 D052616
650    _2
$a hmotnostní spektrometrie s elektrosprejovou ionizací $7 D021241
650    _2
$a tandemová hmotnostní spektrometrie $7 D053719
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vanhara, Petr $u Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Valletta, Elisa $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
700    1_
$a Pinna, Elisabetta $u Dipartimento di Scienze Biomediche, University of Cagliari, Cagliari, Italy.
700    1_
$a Vascellari, Sarah $u Dipartimento di Scienze Biomediche, University of Cagliari, Cagliari, Italy.
700    1_
$a Caddeo, Graziano $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
700    1_
$a Isaia, Francesco $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
700    1_
$a Pani, Alessandra $u Dipartimento di Scienze Biomediche, University of Cagliari, Cagliari, Italy.
700    1_
$a Havel, Josef $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. Department of Chemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Pivetta, Tiziana $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
773    0_
$w MED00004050 $t Rapid communications in mass spectrometry RCM $x 1097-0231 $g Roč. 33, č. 1 (2019), s. 97-106
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30376198 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190416084311 $b ABA008
999    __
$a ok $b bmc $g 1391515 $s 1050510
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 33 $c 1 $d 97-106 $i 1097-0231 $m Rapid communications in mass spectrometry $n Rapid Commun Mass Spectrom $x MED00004050
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options